NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,229.98 +28.71 (+0.17%) CRUDE OIL
82.97 +0.16 (+0.19%) GOLD FUTURES
2,331.30 -7.10 (-0.30%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,504.21 -1,832.42 (-3.44%)
Voyager Therapeutics, Inc. (VYGR)
After hours:
| Previous close | 7.65 |
| Open | 7.65 |
| Bid | 5.50 x 200 |
| Ask | 7.61 x 100 |
| Day's range | 7.45 - 7.66 |
| 52-week range | 6.06 - 14.34 |
| Volume | |
| Avg. volume | 643,261 |
| Market cap | 411.056M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 2.55 |
| EPS (TTM) | 2.97 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.78 |
GlobeNewswireVoyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALSLEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set of data related to its TRACER™ capsid discovery platform and TRACER-driven gene th
- GlobeNewswire
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously a
Simply Wall St.Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Voyager Therapeutics (NASDAQ:VYGR) has had a rough week with its share price down 14%. However, a closer look at its...
